Tianjin Tianyao Pharmaceuticals Denies Acquisition By Pfizer
This article was originally published in PharmAsia News
Tianjin Tianyao Pharmaceuticals, a dominant steroid manufacturer in China, has denied reports that it is in discussion with Pfizer for acquisition (PharmAsia News Jun. 23, 2008). According to company insiders, Tianyao and Pfizer have been collaborating for several years, and Tianyao is a raw material supplier for the pharmaceutical giant which monopolizes the steroid hormone market in China. To date, both parties' partnership has not changed, with Tianyao still a Pfizer's vendor. (Click here for more - Chinese Language)
You may also be interested in...
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.